Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Welcome and Introduction to Vi3C

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mar

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Welcome and Introduction to Vi3C

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Radiotherapy May Reduce Risk of Lymphedema in Patients With Breast Cancer More Effectively Than Surgery

Breast Cancer Recurrence Remains Low Even After 10 Years With Radiotherapy Tailored to Patient’s Individual Risk

Breast Reconstruction Using Polyurethane-Coated Implants May Reduce the Risk of Capsular Contracture, Additional Surgery

AI As Collaborator in Cancer Research and in Clinical Care

Metabolic Subtypes of Nasopharyngeal Carcinoma and Response to Treatment